Low-dose single-shot COVID-19 mRNA vaccines lie ahead

Without an efficient worldwide vaccination campaign, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants will stay endemic in many countries and continue to restrict international socio-economic activities. mRNA vaccines are an important asset in the global fight against coronavirus disease 2019 (COVID-19). The cell-free production makes the manufacturing of mRNA vaccines easier than, for example, protein- and viral vector-based vaccines. Moreover, novel antigens can be rapidly plugged-in, which makes it possible to have mRNA vaccines against new SARS-CoV-2 variants ready for production in about 3 to 4 weeks.